PATENTED TECHNOLOGY

INTELLIGENT FORMULATION,

DOWN TO A SCIENCE

Intelligent formulation for a pMDI using patented, phospholipid-based CO-SUSPENSIONTM Delivery Technology designed to deliver drug crystals to the airways1,2

BEVESPI Inhaler
BEVESPI Inhaler

All images are for illustrative purposes only.

  • Phospholipids are an endogenous component of human lung surfactant3

  • Drug crystals adhere to the phospholipids to form a homogeneous stable suspension4

  • Phospholipids dissolve in the airway releasing drug crystals at sites of deposition2,3,5

All images are for illustrative purposes only.

BEVESPI AEROSPHERE is a pMDI containing the LAMA glycopyrrolate and LABA formoterol fumarate, along with phospholipid porous particles that form the co-suspension with the micronized drug crystals.1

There is no proven correlation between CO-SUSPENSIONTM Delivery Technology and efficacy or safety.